Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of "Buy" from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has received a consensus recommendation of "Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $29.00.

Several analysts recently issued reports on the stock. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. Wedbush reaffirmed an "outperform" rating and set a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC decreased their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 13,964 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $87,414.64. Following the completion of the sale, the chief executive officer directly owned 145,737 shares of the company's stock, valued at $912,313.62. This represents a 8.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Charles N. York II sold 4,282 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the completion of the sale, the chief financial officer directly owned 265,231 shares of the company's stock, valued at approximately $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,725 shares of company stock valued at $167,299 in the last ninety days. Company insiders own 6.20% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at $27,000. Quantbot Technologies LP acquired a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at $82,000. Pallas Capital Advisors LLC acquired a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at $87,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at $88,000. Finally, Magnetar Financial LLC acquired a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at $90,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Stock Up 2.1%

Shares of DAWN traded up $0.14 during mid-day trading on Friday, hitting $6.93. 946,138 shares of the company's stock were exchanged, compared to its average volume of 1,152,733. The firm has a fifty day moving average of $6.60 and a two-hundred day moving average of $8.74. Day One Biopharmaceuticals has a twelve month low of $6.08 and a twelve month high of $16.76. The stock has a market cap of $702.44 million, a price-to-earnings ratio of -9.76 and a beta of -1.27.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.11. Day One Biopharmaceuticals had a negative net margin of 42.66% and a negative return on equity of 14.98%. The company had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million. On average, equities analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.